FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554425960> ?p ?o ?g. }

• W2554425960 endingPage "5077" @default.
• W2554425960 startingPage "5077" @default.
• W2554425960 abstract "Abstract Background: Diffuse large B cell lymphoma is the most frequent Haematological Malignancy in UAE. DLBC lymphoma treatment and outcome are well established. Most of reported outcome data is from North America or Europe. Because of lack of reported literature from Middle East, a retrospective data collection and review was performed in Tawam Hospital to evaluate the outcome of DLBC lymphoma. Methods: Retrospective chart review of all diffuse large B cell lymphoma patients treated from January 1, 2008 till December 30, 2012 at Tawam Hospital, a Tertiary Care Oncology Centre in UAE. Results: A total of 99 patients were identified with diffuse large B cell lymphoma. The median age was 48 (17 to 85). 59% of patients were male with a male to female ratio of 1.4. There were 17 (17%) stage I cases, 27 (27%) stage II cases, 23 (23%) stage III cases, and 30 (30%) stage IV cases. The stage was not documented in 2 (2%) patients. International Prognostic Index (IPI) score was documented in 80 (80%) patients. 28 (35%) of patients had low IPI score (0 or 1 risk factor), 33 (41%) patients had low intermediate IPI score (2 risk factor), 8 (10%) patients had high Intermediate IPI score (3 risk factors) and 11 (14%) patients had high IPI score (4 and 5 risk factors). 88 (89%) patients completed planned treatment: either R-CHOP or R-CHOP like chemotherapy. Involved field radiation therapy (IFRT) was given in limited stage and bulky disease. 11 (11%) patients didn't have a complete treatment. 3 patients received only R-CVP, 4 patients received only 1 cycle R-CHOP, 1 patient did not receive any treatment, 1 patient received only palliative Radiotherapy, 1 patient received Rituximab and palliative RT and 1 patient received only Dexamethasone and Rituximab. Relapse-free patients had median follow up of 31 months (1 to 67). 19 (26%) had less than 12 months follow up after completion of chemotherapy. Patients with documented relapses or primary refractory disease had relapse or progression at a median follow up of 14 month (1 to 43). There were 3 (10%) relapses in Low IPI score, 8 (24%) in low intermediate group, 4 (50%) in high intermediate group and 6 (54%) in high risk group. Discussion: Our data showed more young patients, median age 48, as compared to SEER data median age 65 and male predominance (59%), slightly higher as compared to SEER data (55%). These findings may be related to the demographics of UAE. UAE relatively have young and male predominance partly due to large number of expatriate population. Distribution of IPI score in our data is different as compared to the reported data; low risk 35% vs 52%, low intermediate 41% vs 21%, high intermediate 10% vs17%, and high risk 14% vs10%. Our data is missing reporting of IPI score in 20% of cases, may explain party the above difference. As median follow up of patient without relapse was 34 months, so comparison was made with 3 years progression free survival data reported in literature. Relapse free survival in the Low risk group 90% is comparable to reported 3 years progression free survival of 87% , low intermediate 76% as compared to reported 75%, in High intermediate and High risk group 50% and 46% are close to reported 59% (3) and 50% . The difference in high intermediate and high risk group as compared to reported survival in literature may be due to small number of patients in these groups. Conclusion: Outcome of DLBC lymphoma in our single centre retrospective review is relatively similar to reported outcome in literature. Median age is lower as compared to SEER data. Disclosures No relevant conflicts of interest to declare." @default.
• W2554425960 created "2016-11-30" @default.
• W2554425960 creator A5010549310 @default.
• W2554425960 creator A5011208183 @default.
• W2554425960 creator A5025042508 @default.
• W2554425960 creator A5069756994 @default.
• W2554425960 creator A5086857768 @default.
• W2554425960 creator A5090903348 @default.
• W2554425960 date "2015-12-03" @default.
• W2554425960 modified "2023-09-28" @default.
• W2554425960 title "Outcome of Patients with Diffuse Large B Cell Lymphoma Treated in a Tertiary Care Centre in Uae; A Retrospective Review" @default.
• W2554425960 doi "https://doi.org/10.1182/blood.v126.23.5077.5077" @default.
• W2554425960 hasPublicationYear "2015" @default.
• W2554425960 type Work @default.
• W2554425960 sameAs 2554425960 @default.
• W2554425960 citedByCount "0" @default.
• W2554425960 crossrefType "journal-article" @default.
• W2554425960 hasAuthorship W2554425960A5010549310 @default.
• W2554425960 hasAuthorship W2554425960A5011208183 @default.
• W2554425960 hasAuthorship W2554425960A5025042508 @default.
• W2554425960 hasAuthorship W2554425960A5069756994 @default.
• W2554425960 hasAuthorship W2554425960A5086857768 @default.
• W2554425960 hasAuthorship W2554425960A5090903348 @default.
• W2554425960 hasBestOaLocation W25544259601 @default.
• W2554425960 hasConcept C126322002 @default.
• W2554425960 hasConcept C141071460 @default.
• W2554425960 hasConcept C146357865 @default.
• W2554425960 hasConcept C151730666 @default.
• W2554425960 hasConcept C167135981 @default.
• W2554425960 hasConcept C2778476033 @default.
• W2554425960 hasConcept C2778559949 @default.
• W2554425960 hasConcept C2779338263 @default.
• W2554425960 hasConcept C2779725641 @default.
• W2554425960 hasConcept C71924100 @default.
• W2554425960 hasConcept C86803240 @default.
• W2554425960 hasConceptScore W2554425960C126322002 @default.
• W2554425960 hasConceptScore W2554425960C141071460 @default.
• W2554425960 hasConceptScore W2554425960C146357865 @default.
• W2554425960 hasConceptScore W2554425960C151730666 @default.
• W2554425960 hasConceptScore W2554425960C167135981 @default.
• W2554425960 hasConceptScore W2554425960C2778476033 @default.
• W2554425960 hasConceptScore W2554425960C2778559949 @default.
• W2554425960 hasConceptScore W2554425960C2779338263 @default.
• W2554425960 hasConceptScore W2554425960C2779725641 @default.
• W2554425960 hasConceptScore W2554425960C71924100 @default.
• W2554425960 hasConceptScore W2554425960C86803240 @default.
• W2554425960 hasIssue "23" @default.
• W2554425960 hasLocation W25544259601 @default.
• W2554425960 hasOpenAccess W2554425960 @default.
• W2554425960 hasPrimaryLocation W25544259601 @default.
• W2554425960 hasRelatedWork W1969281389 @default.
• W2554425960 hasRelatedWork W2032099400 @default.
• W2554425960 hasRelatedWork W2051607939 @default.
• W2554425960 hasRelatedWork W2100197564 @default.
• W2554425960 hasRelatedWork W2155499847 @default.
• W2554425960 hasRelatedWork W2292265136 @default.
• W2554425960 hasRelatedWork W2771923871 @default.
• W2554425960 hasRelatedWork W2899250601 @default.
• W2554425960 hasRelatedWork W3210028799 @default.
• W2554425960 hasRelatedWork W79716904 @default.
• W2554425960 hasVolume "126" @default.
• W2554425960 isParatext "false" @default.
• W2554425960 isRetracted "false" @default.
• W2554425960 magId "2554425960" @default.
• W2554425960 workType "article" @default.